imperative the company does not 'speed' the trial without visibility and adjustment within the cohort recruited and retained to completion
'Our experiences have highlighted how patient compliance and the placebo effect could threaten the success of an insomnia trial. The design strategies we implemented to address these variables are already demonstrating their effectiveness'
combine this with the potentially expanded trial sites ( i read it as these 2 go hand in hand) and it becomes clear the company is ensuring the chronic sufferer veracity of the recruited cohort to ensure valid and authentic data is gathered to baseline the medication outcome accuratleyfor insomnia and anxiety.
as the company states - The design strategies we implemented to address these variables are already demonstrating their effectiveness'
this is a very positive statement imo
AVE Price at posting:
0.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)